Blood monitoring could make TB treatment safer for thousands

NCT ID NCT07477119

Recruiting now Disease control Sponsor: Marco Schiuma Source: ClinicalTrials.gov ↗

First seen Mar 21, 2026 · Last updated May 22, 2026 · Updated 7 times

Summary

This study aims to see if adjusting the dose of the drug linezolid based on regular blood tests can reduce harmful side effects in people being treated for multidrug-resistant tuberculosis (MDR-TB). About 150 participants in Guinea will either receive the standard dose or a personalized dose guided by blood drug levels. The goal is to keep the drug at a safe and effective level, potentially lowering the risk of nerve damage and other serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for THERAPEUTIC DRUG MONITORING (TDM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Centre de Santé de Tombolia
RECRUITING

Conakry, Guinea

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

LINEZOLID THERAPEUTIC DRUG MONITORING (TDM) THERAPEUTIC DRUG MONITORING (TDM) TUBERCULOSIS MULTI DRUG RESISTANT ACTIVE TUBERCULOSIS MULTI DRUG RESISTANT ACTIVE